1 week Ago By ABMN Staff
Norges Bank bought a new stake in Integra LifeSciences Holdings Co. ( NASDAQ:IART – Free Report ) in the 4th quarter, HoldingsChannel.com reports.
The firm bought 395,385 shares of the life sciences company’s stock, valued at approximately $8,967,000. Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Nisa Investment Advisors LLC grew its stake in Integra LifeSciences by 599.
6% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after acquiring an additional 2,800 shares during the period. Empowered Funds LLC bought a new position in shares of Integra LifeSciences in the 4th quarter worth $180,000.
Romano Brothers AND Company acquired a new stake in Integra LifeSciences in the 4th quarter valued at $204,000. Mitsubishi UFJ Asset Management UK Ltd. bought a new stake in Integra LifeSciences during the 4th quarter valued at $204,000.
Finally, Centiva Capital LP acquired a new position in Integra LifeSciences during the third quarter worth $192,000. 84.78% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades Separately, Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday, March 31st. Three research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $23.
00. Integra LifeSciences Stock Down 7.7 % IART opened at $18.
07 on Wednesday. Integra LifeSciences Holdings Co. has a fifty-two week low of $16.
81 and a fifty-two week high of $34.79. The firm has a market capitalization of $1.
40 billion, a P/E ratio of -200.76, a PEG ratio of 0.73 and a beta of 1.
24. The company’s 50-day moving average is $22.91 and its 200 day moving average is $22.
32. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.
20 and a quick ratio of 0.73. Integra LifeSciences ( NASDAQ:IART – Get Free Report ) last posted its earnings results on Tuesday, February 25th.
The life sciences company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.85 by $0.
12. The firm had revenue of $442.65 million for the quarter, compared to analysts’ expectations of $445.
15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.
35%. The company’s quarterly revenue was up 11.5% compared to the same quarter last year.
During the same quarter last year, the firm earned $0.89 EPS. Research analysts expect that Integra LifeSciences Holdings Co.
will post 2.45 earnings per share for the current fiscal year. Integra LifeSciences Profile ( Free Report ) Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology.
It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. See Also Want to see what other hedge funds are holding IART? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. ( NASDAQ:IART – Free Report ). Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
